



Press release
17 December 2008

Kringle Pharma Europe AB Established in Sweden

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, “KRINGLE”) and Tripep AB (Head office located in Huddinge, Sweden; CEO: Jan Nilsson, “TRIPEP”) have been engaged in co-development of ChronSeal®, a novel wound healing therapy using recombinant human hepatocyte growth factor (HGF) for venous leg ulcers in Norway and Sweden. (refer to our press release dated December 3, 2008 for details)

To facilitate the co-development efforts for ChronSeal® and push forward its clinical development, KRINGLE and TRIPEP agreed to jointly establish Kringle Pharma Europe AB (“KRINGLE EUROPE”), a consolidated subsidiary of KRINGLE, in Sweden. All the assets related to the ChronSeal® project will be transferred to KRINGLE EUROPE, from the date of its establishment, KRINGLE EUROPE will be a sole vehicle to further the clinical development of ChronSeal® and explore its licensing opportunities.

Overview of the subsidiary

| | |
|---------------------------|---|
| (1) Company name | Kringle Pharma Europe AB |
| (2) Location | Stockholm, Sweden |
| (3) Date of establishment | December 10, 2008 |
| (4) Board members | Kunio Iwatani (Chairman of the Board) Jan Nilsson |
| (5) Share capital | 100,000SEK Shareholding ratio: KRINGLE 75% , TRIPEP 25%. |

Kunio Iwatani stated “Recognizing the fact that phase 2 clinical study of ChronSeal® has already been initiated in Norway from November, I am expecting licensing activities related to ChronSeal® would gain great momentum. By launching KRINGLE EUROPE, KRINGLE will strengthen its efforts to achieve proof of concept (POC) of HGF as a pharmaceutical product and materialize a licensing deal with a pharmaceutical company.”

About Kringle Pharma, Inc.

Kringle Pharma is a biopharmaceutical company established in 2001 to develop novel biologics based on HGF and NK4, both discovered by Professor Emeritus Toshikazu Nakamura at Osaka University. Currently, Kringle’s pipeline consists of human recombinant human HGF for the treatment of 1) acute renal failure, 2) skin ulcers, and 3) CNS diseases, in addition to recombinant human NK4 and NK4 gene drugs for cancer therapy. For more information, please refer to the company’s website: www.kringle-pharma.com/en/index.html.

About ChronSeal®

ChronSeal® is a topical application therapy, having HGF as a main active pharmaceutical ingredient, for chronic leg wounds, a rapidly increasing problem among the elderly population of the World. In cooperation with Swedish partner Tripep AB, a new formulation has been developed that enables the use of ChronSeal® without it being combined with antibiotics. An application for a patent pertaining to an antibiotic-free formulation of ChronSeal® was filed in the US in January 2008.

For more information, please contact:

Tomoya Shimojo, Director of Corporate Planning, Kringle Pharma, Inc.

Tel: +81 6 6831 3330

E-mail: info@kringle-pharma.com